Fosinopril Sodium And Hydrochlorothiazide Tablet
Product Images NDC 69097-972

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Fosinopril Sodium And Hydrochlorothiazide (NDC 69097-972). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10-12-label (10 12 Label)

Label for Fosinopril Sodium and Hydrochlorothiazide Tablets, USP 10 mg / 12.5 mg, oral tablets in a package of 100. The label includes NDC 69097-972-07, manufacturer Cipla USA Inc., and storage instructions. It also displays a barcode and a QR code along with blank placeholders for GTIN, serial number, expiration date, and lot number.*

FDA Label Image

20-12-label (20 12 Label)

Label for Fosinopril Sodium and Hydrochlorothiazide tablets, USP, 20 mg / 12.5 mg strength. The bottle contains 100 tablets. Label indicates Rx Only and lists Cipla as the labeler. Manufacturer is InvaGen Pharmaceuticals, a subsidiary of Cipla Ltd. Additional storage and dosage information is provided on the label.*

FDA Label Image

Fosinopril-structure (Fosinopril Structure)

Chemical structure diagram of Fosinopril Sodium showing its molecular formula C30H45NNaO7P and molecular weight 585.65.*

FDA Label Image

Hydrochlorothiazide-structure (Hydrochlorothiazide Structure)

Chemical structure diagram of Fosinopril Sodium, showing its molecular formula (C7H8ClN3O4S2) and molecular weight (297.73). The structure highlights rings and functional groups relevant to the molecule.*

FDA Label Image

Table1 (Image 03)

A data table comparing the percentage of patients experiencing various adverse events between those taking Fosinopril Sodium and Hydrochlorothiazide tablets and a placebo group. Events listed include headache, cough, fatigue, dizziness, upper respiratory infection, and musculoskeletal pain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.